Safety and efficacy of 48-week pegylated interferon-α-2b therapy in patients with hepatitis B virus-related compensated liver cirrhosis: a pilot observational study

Authors

Institutions

Publication Details

Journal
Frontiers in Medicine
Published
2024-12-04
DOI
https://doi.org/10.3389/fmed.2024.1489671
Citations
5
Primary Topic
Hepatitis B Virus Studies
Type
article
Field-Weighted Citation Impact
1.93

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Safety and efficacy of 48-week pegylated interferon-α-2b therapy in patients with hepatitis B virus-related compensated liver cirrhosis: a pilot observational study

Yongli Hua, Xuanxuan Wang, Shaoyuan Shi, Li Zhou et al.
5 citations
Frontiers in Medicine
Hepatitis B Virus Studies
1.93
article

Safety and efficacy of 48-week pegylated interferon-α-2b therapy in patients with hepatitis B virus-related compensated liver cirrhosis: a pilot observational study

Yongli Hua, Xuanxuan Wang, Shaoyuan Shi, Li Zhou, Zehong Wang, Yinong Feng
article en
5 citations

Abstract

No abstract available for this paper.
Frontiers in MedicineVol. 11
Fourth People's Hospital of Taiyuan (CN)
Wu Jieping Medical Foundation
Good health and well-being
Openalex Percentile: Top 13%
Hepatitis B Virus Studies
1.93
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.